Unknown

Dataset Information

0

A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge.

ABSTRACT: The emergence of SARS-CoV-2 variants of concern (VOC) requires adequate coverage of vaccine protection. We evaluated whether a SARS-CoV-2 spike ferritin nanoparticle vaccine (SpFN), adjuvanted with the Army Liposomal Formulation QS21 (ALFQ), conferred protection against the Alpha (B.1.1.7), and Beta (B.1.351) VOCs in Syrian golden hamsters. SpFN-ALFQ was administered as either single or double-vaccination (0 and 4 week) regimens, using a high (10 μg) or low (0.2 μg) dose. Animals were intranasally challenged at week 11. Binding antibody responses were comparable between high- and low-dose groups. Neutralizing antibody titers were equivalent against WA1, B.1.1.7, and B.1.351 variants following two high dose vaccinations. Dose-dependent SpFN-ALFQ vaccination protected against SARS-CoV-2-induced disease and viral replication following intranasal B.1.1.7 or B.1.351 challenge, as evidenced by reduced weight loss, lung pathology, and lung and nasal turbinate viral burden. These data support the development of SpFN-ALFQ as a broadly protective, next-generation SARS-CoV-2 vaccine.

SUBMITTER: Wuertz KM 

PROVIDER: S-EPMC8553838 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge.

Wuertz Kathryn McGuckin KM   Barkei Erica K EK   Chen Wei-Hung WH   Martinez Elizabeth J EJ   Lakhal-Naouar Ines I   Jagodzinski Linda L LL   Paquin-Proulx Dominic D   Gromowski Gregory D GD   Swafford Isabella I   Ganesh Akshaya A   Dong Ming M   Zeng Xiankun X   Thomas Paul V PV   Sankhala Rajeshwer S RS   Hajduczki Agnes A   Peterson Caroline E CE   Kuklis Caitlin C   Soman Sandrine S   Wieczorek Lindsay L   Zemil Michelle M   Anderson Alexander A   Darden Janice J   Hernandez Heather H   Grove Hannah H   Dussupt Vincent V   Hack Holly H   de la Barrera Rafael R   Zarling Stasya S   Wood James F JF   Froude Jeffrey W JW   Gagne Matthew M   Henry Amy R AR   Mokhtari Elham Bayat EB   Mudvari Prakriti P   Krebs Shelly J SJ   Pekosz Andrew S AS   Currier Jeffrey R JR   Kar Swagata S   Porto Maciel M   Winn Adrienne A   Radzyminski Kamil K   Lewis Mark G MG   Vasan Sandhya S   Suthar Mehul M   Polonis Victoria R VR   Matyas Gary R GR   Boritz Eli A EA   Douek Daniel C DC   Seder Robert A RA   Daye Sharon P SP   Rao Mangala M   Peel Sheila A SA   Joyce M Gordon MG   Bolton Diane L DL   Michael Nelson L NL   Modjarrad Kayvon K  

NPJ vaccines 20211028 1

The emergence of SARS-CoV-2 variants of concern (VOC) requires adequate coverage of vaccine protection. We evaluated whether a SARS-CoV-2 spike ferritin nanoparticle vaccine (SpFN), adjuvanted with the Army Liposomal Formulation QS21 (ALFQ), conferred protection against the Alpha (B.1.1.7), and Beta (B.1.351) VOCs in Syrian golden hamsters. SpFN-ALFQ was administered as either single or double-vaccination (0 and 4 week) regimens, using a high (10 μg) or low (0.2 μg) dose. Animals were intranasal  ...[more]

Similar Datasets

Unknown A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters.
| S-EPMC8219092 | biostudies-literature
Unknown Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques.
| S-EPMC10040355 | biostudies-literature
Unknown Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection.
| S-EPMC7834972 | biostudies-literature
Unknown Lipid nanoparticle encapsulation of a Delta spike-CD40L DNA vaccine improves effectiveness against Omicron challenge in Syrian hamsters.
| S-EPMC11416279 | biostudies-literature
Unknown Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant.
| S-EPMC9157036 | biostudies-literature
Unknown An S1-Nanoparticle Vaccine Protects against SARS-CoV-2 Challenge in K18-hACE2 Mice.
| S-EPMC9327679 | biostudies-literature
Unknown SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses.
| S-EPMC8668928 | biostudies-literature
Unknown A highly effective ferritin-based divalent nanoparticle vaccine shields Syrian hamsters against lethal Nipah virus.
| S-EPMC11191641 | biostudies-literature
Unknown Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease.
| S-EPMC7979827 | biostudies-literature
Unknown CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge.
| S-EPMC8062487 | biostudies-literature